Pubh 8482: Sequential Analysis
|
|
- Victoria Howard
- 6 years ago
- Views:
Transcription
1 Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10
2 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically, we focused on Phase I clinical trials The goal of phase I is to evaluate the safety of a novel chemotherapeutic agent We discussed how this motivates adaptive designs and illustrated the pros and cons of adaptive designs
3 Phase II Clinical Trials Phase II is the second step in drug development Provides a bridge between evaluating toxicity and final, confirmatory clinical trials The focus in Phase II shifts from toxicity to efficacy Phase II clinical trials are much larger than Phase I ( subjects)
4 Phase II Clinical Trials In Phase 1, we collect preliminary data on the safety profile, dose and administration schedule The goal of Phase II is to determine if the new drug has adequate efficacy to motivate a larger, phase III clinical trial In addition, we also further evaluate the toxicity profile of the novel agent Phase II clinical trials can be subdivided as follows: phase IIA trials phase IIB trials
5 Phase IIA The initial assessment of efficacy is made in phase IIA These are usually single arms studies, comparing response rates to historical standards The goal at this phase eliminate ineffective agents
6 Phase IIB Multi-arm studies New drug is compared to standard of care or other experimental agents Goal is to identify most promising drugs for large confirmatory trials
7 Role of Phase II The number of candidate agents being developed has increased rapidly over the atl 20 years Large, confirmatory, phase III clinical trials are expensive time-consuming Phase II provides an important proving grown and allows for the winnowing out of ineffective agents
8 Design of Phase IIA Single-arm, open label studies Phase II trials are relatively small ( 100 subjects) Usually binary endpoints tumor response (i.e. did the tumor shrink?)
9 Stopping for futility in Phase IIA The majority of novel agents will not have acceptable efficacy We would prefer not to waste time and money studying an ineffective drug This motivates the use of two-stage designs that allow early termination for futility
10 Two-stage Simon Design The most popular two-stage design for phase II clinical trials is Simon s two-stage design Simon s two-stage design tests the response probability of a binary endpoint (usually tumor response) Simon s design has one interim analysis and allows early termination for futility but not efficacy There are two versions: Simon s optimal two-stage design Simon s minimax design
11 Two-stage Simon Design: Basic Design Simon s two-stage design is a one-arm design to test p = p 0 vs. p = p a The basic set-up for both designs is as follows Enroll n 1 subjects and let x 1 be the number of responses for the first n 1 subjects If x 1 c 1, stop for futility. Otherwise, enroll n 2 additional subjects and let x 2 be the number of responses for the next x 2 subjects Reject the null hypothesis if x 1 + x 2 > c 2
12 Simon s Optimal two-stage design The goal of Simon s Optimal two-stage design is to find the design that minimizes the expected sample size under the null E [SS p 0 ] = P (x 1 c 1 p 0 ) n 1 + P (x 1 > c 1 p 0 ) (n 1 + n 2 ) among the class of two-stage designs with null hypothesis p 0 alternative hypothesis p a type-i error α type-ii error β
13 Simon s Optimal Minimax design The goal of Simon s Optimal minimax design is to find the design that minimizesthe maximum sample size n 1 + n 2 among the class of two-stage designs with null hypothesis p 0 alternative hypothesis p a type-i error α type-ii error β
14 Simon s Two-stage design: Example Consider a two-stage design with p 0 = 0.2 p a = 0.4 α = 0.1 β = 0.2 Optimal design n 1 = 12, c 1 = 2, n 2 = 13, c 2 = 7 Minimax design n 1 = 14, c 1 = 2, n 2 = 10, c 2 = 7 R code library(clinfun) ph2simon(pu = 0.2, pa = 0.4, ep1 = 0.1, ep2 = 0.2)
15 Extensions to the Simon Design Several alternate multi-stage designs have been proposed Fleming proposed a two-stage design that allows early termination for futility and efficacy Bryant and Day developed a two-stage design that monitors both efficacy and toxicity Ensign et al. and Chen proposed three-stage designs In principle, these can be derived from the methods discussed in the first half of the course and calculating the exact operating characteristics for binomial data
16 Design of Phase IIB Usually larger than phase IIA ( subjects) Randomized, multi-arm studies Endpoints binary (tumor response) survival (time to progression) overall survival would take too long
17 Type I error in phase IIB larger type I error rates are acceptable in phase IIB α can be increased to 0.10 or more This is considered acceptable because the novel agent will be further evaluated in phase III Furthermore, at this point false negatives are a bigger concern than false positives That is, we don t want to miss on a promising drug because of unnecessarily rigid error restrictions
18 Power in phase IIB Phase IIB studies are usually powered to detect a large expected sample size In this case, we are unlikely to find a statistically significant difference between groups One approach to overcome this problem is to embed a one-sample study within a randomized clinical trial In this way, we still have an avenue for advancing to phase III even if a significant difference is not observed between groups
19 Pick-the-Winner Design An alternate approach to randomized designs is the pick-the-winner approach For binary endpoints, the pick-the-winner approach treats patients with the treatment that appears to be the best at enrollment Pick-the-winner designs are designed to control the type-ii error and not the type-i error These designs have much higher power than randomized designs These designs can substantially inflate the type-i error rate
20 Pick-the-Winner Design: Limitations Furthermore, the pick-the-winner is best when there is a clear winner (i.e. when one treatment clearly has the best efficacy) The method struggles when several treatments have similar efficacy In addition, this design will pick a winner regardless if the best treatment has acceptable efficacy There is also no option to terminate early for futility
21 Summary of standard phase-ii designs Standard methods work well in simple cases but have limited flexibility Standard methods can easily accommodate one and two-arm studies but do not perform well with multiple arms In addition, these designs lack the flexibility to accommodate additional research questions
22 Bayesian Adaptive Approaches Predictive probability approach Sequential stopping Adaptive randomization and dose allocation Hierarchical modeling
23 Bayesian Adaptive Approaches Predictive probability approach Sequential stopping Adaptive randomization and dose allocation Hierarchical modeling
24 Predictive Probability Approach Consider the Phase IIA setting of the two-stage Simon Design In Phase IIA, the goal is to establish that the novel agent has adequate efficacy for further evaluation The two-stage Simon design offers an improvement over a fixed-sample design but it somewhat rigid in it s structure One can extends this basic idea using the predictive probability approach
25 Predictive Probability: Basic Approach A maximum sample size is determined before the study begins Interim analyses are completed throughout the study At each interim analysis, we calculate the probability rejecting the null hypothesis if the study reaches full enrollment The decision to continue the study is based on this probability
26 Predictive Probability for binomial data Let Y 1, Y 2,... be i.i.d. Bernoulli random variables with probability p We would like to test the following hypothesis H 0 : p p 0 H 1 : p > p 0 Let N max be the maximum number of subjects we can accrue
27 Likelihood and Prior Let X j = j i=1 Y i The likelihood after the first j observations is L ( X j p ) ( ) j = p X j (1 p) j X j X j We will put a Beta (a, b) prior on p This results in a Beta posterior p x Beta ( a + X j, b + j X j )
28 Predictive Probability For simplicity, assume that we will reject the null hypothesis at study completion if P (p X Nmax ) > γ for a pre-specified γ Let X Nmax j = X Nmax X j = N max i=j+1 Y i At each interim analysis, we will calculate the predictive probability, which is defined as: P ( P ( ) ) p > p 0 X j, X Nmax j > γ Xj
29 Calculating the Predictive Probability The predictive probability is calculated as follows: PP = = I P(p>p0 X j,x Nmax j)>γ f ( x Nmax j p ) f ( p x j ) dxnmax jdp I P(p>p0 X j,x Nmax j)>γ f ( x Nmax j x j ) dxnmax j where the second line integrates out p and makes use of the fact that: X Nmax j x j Beta Binomial ( N max j, a + x j, b + j x j )
30 Calculating the Predictive Probability The previous integral can be re-written as a sum as follows: PP = I P(p>p0 X j,x Nmax j)>γ f ( x Nmax j x j ) dxnmax j = N max j i=0 P ( X Nmax j = i x j ) IP(p>p0 X j,x Nmax j)>γ where P ( X Nmax j = i x j ) is calculated from the beta-binomial distribution
31 Predictive Probability algorithm Identify N max At each interim analysis, we calculate the predictive power (PP) If PP < θ L, stop the trial and reject the alternative hypothesis If PP > θ U, stop the trial and reject the null hypothesis Otherwise, continue the trial until N max is reached
32 Predictive Probability Example Consider a phase IIA trial with the following characteristics N max = 40 p 0 = 0.60 γ = 0.90 Beta (0.6, 0.4) prior on p
33 Predictive Probability Example Consider an interim analysis with j = 23 and x j = 16 p x j Beta (16.6, 24.4) X Nmax j Beta Binomial (17, 16.6, 7.4) p x j, X Nmax j = i Beta ( i, 24.4 i)
34 Predictive Probability Example i P ( ) X Nmax j = i x j P ( p > 0.60 x j, X Nmax j = i ) I P(p>0.60 xj,x Nmax j =i)>
35 Predictive Probability Example P ( p > 0.60 x j, X Nmax j = i ) < 0.90 for i = 1,..., 11 P ( p > 0.60 x j, X Nmax j = i ) > 0.90 for i = 12,..., 17 Therefore, the predictive probability is P ( X Nmax j 12,..., 17 ) = If, say, θ L = 0.10 and θ U = 0.90, then the trial continues to enroll more subjects
36 Frequency of Interim Analyses In principle, these calculations can be completed after each subject Berry et al. recommend calculating predictive probabilities after each subject starting with the tenth subject Alternately, you could calculate the predictive probability after every 5 or 10 subjects This should be specified in advance
37 Designing a Predictive Probability Trial We must specify the following parameters: N max, γ, θ L and θ U We would like to identify a design that achieves the desired type-i error rate and power Design that achieve the desired operating characteristics can be found by searching for parameter combinations that achieve the desired operating characteristics
38 Designing a Predictive Probability Trial: Example Consider a phase II clinical trial to test the tumor response for a novel treatment p 0 = 0.2 p 1 = 0.4 α = β = 0.10
39 Designing a Predictive Probability Trial: Example Simon s optimal two-stage design n 1 = 17, c 1 = 3, n 2 = 20, c 2 = 10 Simon s Minimax two-stage design n 1 = 19, c 1 = 3, n 2 = 17, c 2 = 10
40 Designing a Predictive Probability Trial: Example The desired operating characteristics can be achieved by many combinations of N max, γ, θ L and θ U One particular design is N max = 37 γ = 0.90 θ L = θ U = 1.0 (i.e. only allow early termination for futility)
41 Designing a Predictive Probability Trial: Example Design E (N p 0 ) α β Optimal Minimax Predictive Probability
42 Predictive Probability Designs Decision to terminate the trial is based on the predictive probability Predictive probability is the probability of rejecting the null hypothesis if the study were to continue to the maximum sample size We illustrated that the predictive probability design can have better operating characteristics than the Simon design The drawback being that they are a bit more complicated and require more continuous monitoring
43 Sequential Stopping for Efficacy and Futility The predictive probability approach uses the probability of rejecting had we reached full enrollment as the basis for early termination Alternately, we could follow a similar approach to identifying stopping as was used in the first half of the course That is, we specifying a statistical model and determine critical values that produce the desired operating characteristics
44 Sequential Stopping for Efficacy and Futility Consider the simplest case of a one-arm trial to evaluate the response rate of a new treatment y 1,..., y nmax i.i.d Bern (p) Let p = p 0 be the rate of response for the standard of care We would like to show that the new treatment improves the response rate by at least δ to warrant further investigation That is, p > p 0 + δ to warrant further investigation
45 Sequential Stopping for Efficacy and Futility: Decision Rules Sequentially monitoring of the null hypothesis is carried out by evaluating the following posterior probability π n = P (p > p 0 + δ y 1,..., y n ) Decisions to continue would be based on the following rule: if π n > U n, stop for efficacy if L n < π n < U n, continue if π n < L n, stop for futility
46 Sequential Stopping for Efficacy and Futility: Decision Rules The primary difference between this approach and the group sequential procedures discussed earlier in the class is that we are proposing continuous monitoring L n and U n can be any shape as before One simple approach is to make L n and U n constants L n and U n are set to achieve the desired operating characteristics
47 Sequential Stopping for Efficacy and Futility: Operating Characteristics In principle, operating characteristics can be calculated analytically for binomial endpoints This can be very difficult in the case of continuous monitoring An alternate approach is to evaluate the design via simulation We iteratively evaluate combinations of U n and L n to identify combinations that achieve the desired operating characteristics
48 Sequential Stopping for Efficacy and Futility: Example Consider a one-arm trial to evaluate the response rate of a novel agent We will assume a Beta (1, 1) prior for the response probability, p The posterior ( after each subject will be Beta 1 + j i=1 y i, 1 + j ) j i=1 The response rate for the standard of care if p 0 = 0.20 The new treatment would have to have a response rate greater than p = 0.30 to warrant further investigation
49 Sequential Stopping for Efficacy and Futility: Example We would like to limit the type-i error rate to 0.10 In this case, the type-i error rate is the probability of concluding that the drug is promising if p < p 0 We would like 90% power to reject the null hypothesis for some p > p 0 + δ For this example, we power our study assuming a response rate of 0.4
50 Sequential Stopping for Efficacy and Futility: Example We evaluate the operating characteristics of our study using simulation We can vary the following parameters U n L n N mas r, the first subject at which we are willing to terminate the study
51 Sequential Stopping for Efficacy and Futility: Example N max r L n U n α E (SS p = 0.20) 1 β E (SS p = 0.40)
52 Sequential Stopping for Efficacy and Futility: Example The design with N max = 90, r = 5, L n = 0.05 and U n = 0.90 had the following operating characteristics α = β = E (SS p = 0.20) = 35.7 E (SS p = 0.40) = 25.0
53 Sequential Stopping for Efficacy and Futility: Example Tweaking the design slightly to N max = 90, r = 5, L n = 0.05 and U n = 0.88 results in the following operating characteristics α = β = E (SS p = 0.20) = 35.4 E (SS p = 0.40) = 23.2 In comparison, a fixed-sample design would require approximately 40 subjects
54 Sequential Stopping for Efficacy and Futility: Example The preceding was a somewhat haphazard search but illustrated the basic principles In reality, there are many designs that result in the correct type-i and type-ii error rates In practice, one should complete a thorough search and compare the expected sample sizes of several potential designs
55 Sequential Stopping for Efficacy, Futility and Toxicity The previous design considers early termination for efficacy and futility but ultimately only considers one outcome: response In phase II, we are also interested in further evaluating the toxicity profile of a new drug In addition, only a smaller number of subjects were used in phase I and we need to protect against a drug that is excessively toxic This motivates extensions to the previous designs that consider early termination for toxicity as well as efficacy and futility
56 Sequential Stopping for Efficacy, Futility and Toxicity Thall et al (1995) extended the previous design to accommodate sequential stopping for efficacy, futility and toxicity This is essentially a phase IIA analog to the efficacy/toxicity trade-off designs we discussed for phase I The difference, though, is that we only consider a single dose and, therefore, the focus is on testing rather than dose-finding
57 Sequential Stopping for Efficacy, Futility and Toxicity: Outcomes We are now considering two, binary outcomes: Efficacy: tumor response Toxicity: toxicity vs. no toxicity This can be thought of as a multinomial random variable A 1 : response with toxicity A 2 : no response with toxicity A 3 : response with no toxicity A 4 : no response and no toxicity In this case: efficacy = A 1 A 3 toxicity = A 1 A 2
58 Sequential Stopping for Efficacy, Futility and Toxicity: Probability Model We assume that our data follow a multinomial distribution with probabilities (p 1, p 2, p 3, p 4 ) We assume a Dirichlet prior for (p 1, p 2, p 3, p 4 ): (p 1, p 2, p 3, p 4 ) Dir (θ 1, θ 2, θ 3, θ 4 ) This results in the following posterior distribution: (p 1, p 2, p 3, p 4 ) y Dir (θ 1 + y 1, θ 2 + y 2, θ 3 + y 3, θ 4 + y 4 ) Where y 1 : y 4 are the counts for each of the four outcomes
59 Sequential Stopping for Efficacy, Futility and Toxicity: Probability Model We will make decisions by monitoring the marginal probabilities of efficacy and toxicity P (efficacy) = p E = p 1 + p 3 P (toxicity) = p T = p 1 + p 2 The posterior distributions for each of these two probabilities are: p E Beta (θ 1 + y 1 + θ 3 + y 3, θ 2 + y 2 + θ 4 + y 4 ) p E Beta (θ 1 + y 1 + θ 2 + y 2, θ 3 + y 3 + θ 4 + y 4 ) This is due to the Beta distribution being a special case of the Dirichlet distribution with only two probabilities
60 Sequential Stopping for Efficacy, Futility and Toxicity: Probability Model We will make decisions by monitoring the marginal probabilities of efficacy and toxicity P (efficacy) = p E = p 1 + p 3 P (toxicity) = p T = p 1 + p 2 The posterior distributions for each of these two probabilities are: p E Beta (θ 1 + y 1 + θ 3 + y 3, θ 2 + y 2 + θ 4 + y 4 ) p T Beta (θ 1 + y 1 + θ 2 + y 2, θ 3 + y 3 + θ 4 + y 4 ) This is due to the Beta distribution being a special case of the Dirichlet distribution with only two probabilities
61 Sequential Stopping for Efficacy, Futility and Toxicity: Decision rules Let p E,s be the probability of response for the standard of care Let p T,s be the probability of toxicity for the standard of care We make our decisions about terminating the trial based on similar posterior probabilities as before π n,e = P ( p E > p E,s + δ E y ) π n,t = P ( p T > p T,s + δ T y )
62 Sequential Stopping for Efficacy, Futility and Toxicity: Decision rules The previous probabilities can be interpreted as follows: We hope to show that the new drug resulted in an improved response rate We do not want the probability of toxicity to exceed the standard of care by more than a small amount
63 Sequential Stopping for Efficacy, Futility and Toxicity: Sequential Monitoring The decision to continue is now updated to the following: if π n,e > U n,e and π n,t < U n,t, stop for efficacy if π n,e < L n,e, stop for futility if π n,t > U n,t, stop for excess toxicity otherwise, continue
64 Sequential Stopping for Efficacy, Futility and Toxicity: Operating Characteristics The study can be designed to achieve the desired operating characteristic by altering the following parameters U n,e : controls stopping for efficacy L n,e : controls stopping for futility U n,t : controls stopping for excess toxicity The operating characteristics of this design can be evaluated by simulation U n,e, L n,e and U n,t are chosen through an iterative procedure, as before
65 Sequential Stopping for Efficacy, Futility and Toxicity: Operating Characteristics It should be noted that there are now four possible true scenarios Improved efficacy, acceptable toxicity Improved efficacy, unacceptable toxicity unacceptable efficacy, acceptable toxicity unacceptable efficacy, unacceptable toxicity but only two possible conclusions drug is promising (i.e. safe and efficacious) drug is not promising This complicates standard concepts of type-i error and power You should consider the probability of rejecting under each scenario
66 Sequential Stopping in Phase II: Summary We discussed two scenarios for sequential monitoring in Phase II: Sequential stopping for efficacy and futility Sequential stopping for efficacy, futility and toxicity These methods are similar to the group sequential procedures discussed in the first half of the course Specify a probability model Develop critical values that result in desired operating characteristics These designs utilize continuous monitoring, which can reduce expected sample size Continuous monitoring also increases the burden on study personnel
67 Multiple Subpopulations The previous designs are appropriate for evaluating a novel agent in a single disease We are often interested in evaluating the efficacy of a novel agent in several diseases We may not have identified a target disease after phase I We have several potential targets but need to narrow down for phase III We are interested in the efficacy of the novel agents in sub-populations of a single disease
68 Pooling Across Groups One approach to the previous problem is to pool across diseases This only makes sense if the drug is equally efficacious for the various diseases It is more likely that the drug has different effects in the various populations, making interpretation difficult Furthermore, the drug could be very effective in one disease but the effect could be washed out because the drug is ineffective for other diseases
69 Running Individual Trials Instead, you could run individual clinical trials for each disease or sub-population This avoids the problems of pooling but is inefficient: Running multiple trials is time-consuming and expensive There may not be enough subjects to run multiple trials It is also possible that there is information about the effectiveness of the drug in one disease can be found in the other trials
70 Hierarchical Modeling in Phase II An alternate approach is to model the data hierarchically This allows information to be shared across the various disease classifications or sub-populations This avoids the problem of pooling across populations that may be different This will also be more efficient than running independent trials for each population
71 Hierarchical Modeling: Basic Approach Let j = 1,..., J index J sub-populations Let y j and θ j generically represent the data and parameters The data are modeled hierarchically as follows: P (y j θ j ) P (θ j φ) φ controls the borrowing of information across groups
72 Hierarchical Modeling: Binary Data Recall that in phase II, the outcome is usually tumor response, measured as a binary outcome Let y j be the number of responses from n j subjects for sub-population j y j Bin ( n j, p j ) where p j is the probability of tumor response for sub-population j
73 Hierarchical Modeling: Modeling p j The probability of tumor response, p j, is transformed using the logit transformation θ j = log ( p j / ( 1 p j )) We put a normal prior on θ j to facilitate the borrowing of information across groups θ j N (µ, τ)
74 Hierarchical Modeling: Hyperparameters We put a normal hyperprior on µ µ N (m µ, s µ ) And a gamma hyperprior on τ τ Gamma (a 0, b 0 )
75 Hierarchical Modeling: Conducting the Trial The previous model allows us to share information across sub-populations This does not fundamentally change how the trial is conducted The decision as to whether or not to continue the trial is made for each sub-population We may terminate the study within one sub-population while the others continues The trial continues until all sub-populations have terminated or reached a maximum sample size
76 Randomization in Phase II We have so far only discussed methods for phase IIA clinical trials Phase IIA trials are single arm trials comparing measures of efficacy to historical standards In Phase IIB, we begin to consider randomized trials to evaluate a novel agent Randomize subjects to novel treatment or standard of care Randomize subjects to one of several novel treatments
77 Standard Randomization The standard approach to randomizing subjects is to specify a fixed randomization ratio at the beginning of the study 1:1 - treatment:control 2:1 - treatment:control The disadvantage to this approach is that a large number of subjects may be randomized to an ineffective treatment In addition, it may be beneficial to limit enrollment to a subset of treatments that appear promising in a trial where several treatments are being considered
78 Adaptive Randomization An alternate approach is adaptive randomization In adaptive randomization, we adapt the randomization ratio based on interim results We increase the number of subjects randomized to promising treatments and limit the number randomized to ineffective treatments This has the advantage of maximizing the number of subjects receiving optimal care
79 Adaptive Randomization Adaptive randomization has been studied extensively throughout the history of statistics (Thompson, 1933, Louis, 1975, 1977) Thall and Wathen (2007) provide a review of adaptive randomization They propose a practical approach to adaptive randomization
80 Basic Approach Let A 1 and A 2 be the two arms of the trial Let θ 1 and θ 2 be the response rate for each arm If y represents the available data, we would randomize subjects at A 1 and A 2 with probabilities proportional to P ( θ 1 > θ 2 y ) c ( 1 P ( θ 1 > θ 2 y )) c c = n, where N is the maximum number of patients 2N
81 Basic Approach Let N = 100 and P (θ 1 > θ 2 y) = 0.7 This results in the following randomization ratios at various times in the study n = 20, randomize (.7/.3) 20/200 : 1 or 1.09 : 1 n = 60, randomize (.7/.3) 60/200 : 1 or 1.29 : 1 n = 90, randomize (.7/.3) 90/200 : 1 or 1.46 : 1
82 Generalizing to Multiple Groups This approach can easily be generalized to more than two groups In the case of more than 2 groups, the probability of being randomized to each arm is proportional to: P ( θ j = max k θ k y ) c
83 Generalizing to Multiple Groups: Example Let N = 100 P ( θ 1 = max k θ k y ) = 0.3 P ( θ 2 = max k θ k y ) = 0.5 P ( θ 3 = max k θ k y ) = 0.2 This results in the following randomization ratios at various times in the study n = 20, randomize 1.04:1.10:1 n = 60, randomize 1.13:1.32:1 n = 90, randomize 1.20:1.51:1
84 Conducting an Adaptive Randomization Trial Start by identifying a maximum sample size Subjects will be enrolled and sequentially monitored using continuous or group sequential monitoring We must specify the following decision rules for terminating the study early loser early winner futility final winner
85 Early Loser Enrollment in an arm will stop if there is overwhelming evidence that the arm is not the best treatment This can be formalized as the following: P ( θ j = max k θ k y ) < p L That is, the probability that treatment j is the best is very low In this case, enrollment in treatment j would stop and the trial continues only with the remaining treatments
86 Early Winner The trial stops and we identify the best treatment when there is overwhelming evidence that treatment j is the best treatment Formally, we stop and declare treatment j the winner if P ( θ j = max k θ k y ) > p U In this case, the trial terminates and we declare treatment j the winner
87 Futility We could also stop an arm for futility if there is overwhelming evidence that the treatment does not meet some historical standard Formally P ( θ j > θ min y ) < P F In this case, enrollment in arm j stops and the trial continues with the other arms
88 Final Winner At study completion, we identify treatment j as the best treatment if there is strong evidence that it is the best That is, P ( θ j = max k θ k y ) > p U,final p U,final is set less than p U to increase the chance of picking a winner No treatment is selected if the above statement is false for all arms
89 Monitoring an Adaptive Randomization Trial At study initiation, subjects are randomized equally to each arm The randomization ratios are updated throughout the study based on the available data Individual arms or the entire study are terminated based on the pre-specified stopping rules If the study does not terminate early, the final decision is made at the maximum sample size using the pre-specified decision rule
90 Designing an Adaptive Randomization Trial As before, the operating characteristics of our study are not usually available analytically Instead, we conduct simulation studies to evaluate our design Simulations are completed under a variety of scenarios and identify design parameters that result in acceptable characteristics in a variety of settings
91 Adaptive Randomization: Example Consider the following example from Berry et al (2012) Researchers would like to complete a phase II clinical trial to evaluate a novel sensitizer that enhances the efficacy of chemotherapy when given in combination This will be a two-arm study Arm 1 - chemotherapy alone Arm 2 - chemotherapy + sensitizer
92 Adaptive Randomization: Example We would like to compare the response rate for the two arms The clinician has good prior information on the two arms and prior distributions for the response rates were derived using the following prior mean and standard deviation for each response rate Arm 1 - prior mean = 0.55, prior standard deviation = 0.10 Arm 2 - prior mean = 0.75, prior standard deviation = 0.13 Beta priors for the two response rates can be derived from the prior mean and standard deviation for each response rate
93 Adaptive Randomization: Example Consider a design with the following parameters Maximum sample size = 60 P L = P U = θ min = 0.50 and P F = 0.05 P U,final = 0.90 Operating characteristics of our study can be evaluated by simulation
94 Operating Characteristics: Null Hypothesis Arm P (Eff ) P (Sel) P (ES) P (stop) ASN (2.5%, 97.5%) Arm (5, 38) Arm (8, 53)
95 Operating Characteristics: Alternative Hypothesis Arm P (Eff ) P (Sel) P (ES) P (stop) ASN (2.5%, 97.5%) Arm (4, 22) Arm (4, 51)
96 Operating Characteristics: Best Case Scenario Arm P (Eff ) P (Sel) P (ES) P (stop) ASN (2.5%, 97.5%) Arm (4, 16) Arm (4, 51)
97 Adaptive Randomization: Operating Characteristics The adaptive design has a type-i error rate of 17% and 74% power The expected sample size under each scenario is: null hypothesis: 55 alternative hypothesis: 41 best case scenario: 27 In contrast, a corresponding fixed-sample design would require 67 subjects/group
98 Adaptive Randomization: Operating Characteristics These simulations results represent the operating characteristics in only a small number of scenarios In practice, you would consider a much broader set of scenarios In addition, you may also vary design parameters to determine their impact on the operating characteristics priors for response rates stopping rule parameters
99 Adaptive Randomization: Summary Standard randomized designs randomize subjects using a fixed ratio This results in a large number of subjects randomized to inferior treatments Adaptive randomization updates randomization allocation as study continues This results in shorter trials and more subjects treated with better treatments
100 Phase II Summary Phase II clinical trials provide the first look at the efficacy of a novel agent The goal of Phase II is to determine if a novel agent has sufficient efficacy to warrant a much larger phase II clinical trials In addition, we hope to answer several secondary questions about the drug best dose optimal population
101 Phase II Summary The wide array of questions asked in phase II motivates the use of adaptive designs We discussed several approaches to adaptive trial design in phase II predictive probability sequential monitoring hierarchical modeling adaptive randomization The goal of these methods is to answer our scientific question as quickly as possible and to treat as many subjects as possible with the optimal treatment
Pubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 12 Review So far... We have discussed the role of phase III clinical trials in drug development
More informationCHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity
CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity Prof. Kevin E. Thorpe Dept. of Public Health Sciences University of Toronto Objectives 1. Be able to distinguish among the various
More informationAdaptive Designs: Why, How and When?
Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:
More informationType I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Frank Bretz Statistical Methodology, Novartis Joint work with Martin Posch (Medical University
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 5 Course Summary So far, we have discussed Group sequential procedures for two-sided tests Group
More informationComparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design
Comparing Adaptive Designs and the Classical Group Sequential Approach to Clinical Trial Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 8 P-values When reporting results, we usually report p-values in place of reporting whether or
More informationThe Design of a Survival Study
The Design of a Survival Study The design of survival studies are usually based on the logrank test, and sometimes assumes the exponential distribution. As in standard designs, the power depends on The
More informationGroup-Sequential Tests for One Proportion in a Fleming Design
Chapter 126 Group-Sequential Tests for One Proportion in a Fleming Design Introduction This procedure computes power and sample size for the single-arm group-sequential (multiple-stage) designs of Fleming
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 7 Course Summary To this point, we have discussed group sequential testing focusing on Maintaining
More informationA PREDICTIVE PROBABILITY INTERIM DESIGN FOR PHASE II CLINICAL TRIALS WITH CONTINUOUS ENDPOINTS
University of Kentucky UKnowledge Theses and Dissertations--Epidemiology and Biostatistics College of Public Health 2017 A PREDICTIVE PROBABILITY INTERIM DESIGN FOR PHASE II CLINICAL TRIALS WITH CONTINUOUS
More informationBios 6649: Clinical Trials - Statistical Design and Monitoring
Bios 6649: Clinical Trials - Statistical Design and Monitoring Spring Semester 2015 John M. Kittelson Department of Biostatistics & Informatics Colorado School of Public Health University of Colorado Denver
More informationDivision of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series
Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series Year: 2013 #006 The Expected Value of Information in Prospective Drug Safety Monitoring Jessica M. Franklin a, Amanda R. Patrick
More informationarxiv: v1 [stat.me] 24 Jul 2013
arxiv:1307.6275v1 [stat.me] 24 Jul 2013 A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy Daniel Zelterman Department of Biostatistics School of Epidemiology
More informationInterim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping
Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationOptimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping
: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology
More informationBayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
Guo and Li BMC Medical Research Methodology 2014, 14:95 RESEARCH ARTICLE Open Access Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
More informationTwo-stage Adaptive Randomization for Delayed Response in Clinical Trials
Two-stage Adaptive Randomization for Delayed Response in Clinical Trials Guosheng Yin Department of Statistics and Actuarial Science The University of Hong Kong Joint work with J. Xu PSI and RSS Journal
More informationBayesian Enhancement Two-Stage Design for Single-Arm Phase II Clinical. Trials with Binary and Time-to-Event Endpoints
Biometrics 64, 1?? December 2008 DOI: 10.1111/j.1541-0420.2005.00454.x Bayesian Enhancement Two-Stage Design for Single-Arm Phase II Clinical Trials with Binary and Time-to-Event Endpoints Haolun Shi and
More informationDuke University. Duke Biostatistics and Bioinformatics (B&B) Working Paper Series. Randomized Phase II Clinical Trials using Fisher s Exact Test
Duke University Duke Biostatistics and Bioinformatics (B&B) Working Paper Series Year 2010 Paper 7 Randomized Phase II Clinical Trials using Fisher s Exact Test Sin-Ho Jung sinho.jung@duke.edu This working
More informationSample size re-estimation in clinical trials. Dealing with those unknowns. Chris Jennison. University of Kyoto, January 2018
Sample Size Re-estimation in Clinical Trials: Dealing with those unknowns Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj University of Kyoto,
More information4. Issues in Trial Monitoring
4. Issues in Trial Monitoring 4.1 Elements of Trial Monitoring Monitoring trial process and quality Infrastructure requirements and DSMBs 4.2 Interim analyses: group sequential trial design 4.3 Group sequential
More informationGroup Sequential Designs: Theory, Computation and Optimisation
Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference
More informationSequential Monitoring of Clinical Trials Session 4 - Bayesian Evaluation of Group Sequential Designs
Sequential Monitoring of Clinical Trials Session 4 - Bayesian Evaluation of Group Sequential Designs Presented August 8-10, 2012 Daniel L. Gillen Department of Statistics University of California, Irvine
More informationOptimal Designs for Two-Arm Randomized Phase II Clinical Trials with Multiple Constraints. Wei Jiang
Optimal Designs for Two-Arm Randomized Phase II Clinical Trials with Multiple Constraints By Wei Jiang Submitted to the graduate degree program in Biostatistics and the Graduate Faculty of the University
More informationAdaptive Dunnett Tests for Treatment Selection
s for Treatment Selection Franz König 1 Werner Brannath 1 Frank Bretz 2 Martin Posch 1 1 Section of Medical Statistics Medical University of Vienna 2 Novartis Pharma AG Basel Workshop Adaptive Designs
More informationBayesian Optimal Interval Design for Phase I Clinical Trials
Bayesian Optimal Interval Design for Phase I Clinical Trials Department of Biostatistics The University of Texas, MD Anderson Cancer Center Joint work with Suyu Liu Phase I oncology trials The goal of
More informationStatistical Aspects of Futility Analyses. Kevin J Carroll. nd 2013
Statistical Aspects of Futility Analyses Kevin J Carroll March Spring 222013 nd 2013 1 Contents Introduction The Problem in Statistical Terms Defining Futility Three Common Futility Rules The Maths An
More informationMultiple Testing in Group Sequential Clinical Trials
Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas txz122@utdallas.edu 7/2/213 1 Sequential statistics
More informationHierarchical Models & Bayesian Model Selection
Hierarchical Models & Bayesian Model Selection Geoffrey Roeder Departments of Computer Science and Statistics University of British Columbia Jan. 20, 2016 Contact information Please report any typos or
More informationUsing Historical Experimental Information in the Bayesian Analysis of Reproduction Toxicological Experimental Results
Using Historical Experimental Information in the Bayesian Analysis of Reproduction Toxicological Experimental Results Jing Zhang Miami University August 12, 2014 Jing Zhang (Miami University) Using Historical
More informationBios 6649: Clinical Trials - Statistical Design and Monitoring
Bios 6649: Clinical Trials - Statistical Design and Monitoring Spring Semester 2015 John M. Kittelson Department of Biostatistics & Informatics Colorado School of Public Health University of Colorado Denver
More informationAdaptive designs beyond p-value combination methods. Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013
Adaptive designs beyond p-value combination methods Ekkehard Glimm, Novartis Pharma EAST user group meeting Basel, 31 May 2013 Outline Introduction Combination-p-value method and conditional error function
More informationSample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure
Ciarleglio and Arendt Trials (2017) 18:83 DOI 10.1186/s13063-017-1791-0 METHODOLOGY Open Access Sample size determination for a binary response in a superiority clinical trial using a hybrid classical
More informationBAYESIAN STATISTICAL ANALYSIS IN A PHASE II DOSE-FINDING TRIAL WITH SURVIVAL ENDPOINT IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
BAYESIAN STATISTICAL ANALYSIS IN A PHASE II DOSE-FINDING TRIAL WITH SURVIVAL ENDPOINT IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA By SHIANSONG LI A dissertation submitted to the School of Public
More informationDose-response modeling with bivariate binary data under model uncertainty
Dose-response modeling with bivariate binary data under model uncertainty Bernhard Klingenberg 1 1 Department of Mathematics and Statistics, Williams College, Williamstown, MA, 01267 and Institute of Statistics,
More informationInverse Sampling for McNemar s Test
International Journal of Statistics and Probability; Vol. 6, No. 1; January 27 ISSN 1927-7032 E-ISSN 1927-7040 Published by Canadian Center of Science and Education Inverse Sampling for McNemar s Test
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH The First Step: SAMPLE SIZE DETERMINATION THE ULTIMATE GOAL The most important, ultimate step of any of clinical research is to do draw inferences;
More informationPower assessment in group sequential design with multiple biomarker subgroups for multiplicity problem
Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong
More informationCase Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial William R. Gillespie Pharsight Corporation Cary, North Carolina, USA PAGE 2003 Verona,
More informationBayesian Methods for Machine Learning
Bayesian Methods for Machine Learning CS 584: Big Data Analytics Material adapted from Radford Neal s tutorial (http://ftp.cs.utoronto.ca/pub/radford/bayes-tut.pdf), Zoubin Ghahramni (http://hunch.net/~coms-4771/zoubin_ghahramani_bayesian_learning.pdf),
More informationTesting a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials
Testing a secondary endpoint after a group sequential test Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 9th Annual Adaptive Designs in
More informationSuperiority by a Margin Tests for One Proportion
Chapter 103 Superiority by a Margin Tests for One Proportion Introduction This module provides power analysis and sample size calculation for one-sample proportion tests in which the researcher is testing
More informationSample Size Determination
Sample Size Determination 018 The number of subjects in a clinical study should always be large enough to provide a reliable answer to the question(s addressed. The sample size is usually determined by
More informationPubH 5450 Biostatistics I Prof. Carlin. Lecture 13
PubH 5450 Biostatistics I Prof. Carlin Lecture 13 Outline Outline Sample Size Counts, Rates and Proportions Part I Sample Size Type I Error and Power Type I error rate: probability of rejecting the null
More informationAdaptive Trial Designs
Adaptive Trial Designs Wenjing Zheng, Ph.D. Methods Core Seminar Center for AIDS Prevention Studies University of California, San Francisco Nov. 17 th, 2015 Trial Design! Ethical:!eg.! Safety!! Efficacy!
More informationOverrunning in Clinical Trials: a Methodological Review
Overrunning in Clinical Trials: a Methodological Review Dario Gregori Unit of Biostatistics, Epidemiology and Public Health Department of Cardiac, Thoracic and Vascular Sciences dario.gregori@unipd.it
More informationGroup sequential designs for Clinical Trials with multiple treatment arms
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework
More informationSample Size Estimation for Studies of High-Dimensional Data
Sample Size Estimation for Studies of High-Dimensional Data James J. Chen, Ph.D. National Center for Toxicological Research Food and Drug Administration June 3, 2009 China Medical University Taichung,
More informationAn Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary
An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary Ying Zhang and William R. Clarke Department of Biostatistics, University of Iowa 200 Hawkins Dr. C-22 GH, Iowa City,
More informationGroup Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Lisa Hampson Department of Mathematics and Statistics,
More informationA simulation study for comparing testing statistics in response-adaptive randomization
RESEARCH ARTICLE Open Access A simulation study for comparing testing statistics in response-adaptive randomization Xuemin Gu 1, J Jack Lee 2* Abstract Background: Response-adaptive randomizations are
More informationTwo-stage k-sample designs for the ordered alternative problem
Two-stage k-sample designs for the ordered alternative problem Guogen Shan, Alan D. Hutson, and Gregory E. Wilding Department of Biostatistics,University at Buffalo, Buffalo, NY 14214, USA July 18, 2011
More informationBayesian Uncertainty Directed Trial Designs arxiv: v1 [stat.ap] 29 Jun 2018
Bayesian Uncertainty Directed Trial Designs arxiv:1806.11370v1 [stat.ap] 29 Jun 2018 Steffen Ventz 1,2,, Matteo Cellamare 1,2,, Sergio Bacallado 3, and Lorenzo Trippa 1,2 1 Dana-Farber Cancer Institute,
More informationMETHODS OF EVALUATION OF PERFORMANCE OF ADAPTIVE DESIGNS ON TREATMENT EFFECT INTERVALS AND METHODS OF
METHODS OF EVALUATION OF PERFORMANCE OF ADAPTIVE DESIGNS ON TREATMENT EFFECT INTERVALS AND METHODS OF DESIGNING TWO-STAGE WINNER DESIGNS WITH SURVIVAL OUTCOMES BY FANG FANG A dissertation submitted to
More informationThe Limb-Leaf Design:
The Limb-Leaf Design: A New Way to Explore the Dose Response Curve in Adaptive Seamless Phase II/III Trials John Spivack Submitted in partial fulfillment of the Requirements for the degree of Doctor of
More informationSAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE SEQUENTIAL DESIGN IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 18: 1184 1196, 2008 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400802369053 SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE
More informationModeling & Simulation to Improve the Design of Clinical Trials
Modeling & Simulation to Improve the Design of Clinical Trials Gary L. Rosner Oncology Biostatistics and Bioinformatics The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Joint work with Lorenzo
More informationAdaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests.
1/35 Adaptive, graph based multiple testing procedures and a uniform improvement of Bonferroni type tests. Martin Posch Center for Medical Statistics, Informatics and Intelligent Systems Medical University
More informationDesigns for Clinical Trials
Designs for Clinical Trials Chapter 5 Reading Instructions 5.: Introduction 5.: Parallel Group Designs (read) 5.3: Cluster Randomized Designs (less important) 5.4: Crossover Designs (read+copies) 5.5:
More informationPart 7: Hierarchical Modeling
Part 7: Hierarchical Modeling!1 Nested data It is common for data to be nested: i.e., observations on subjects are organized by a hierarchy Such data are often called hierarchical or multilevel For example,
More informationIntroductory Econometrics
Session 4 - Testing hypotheses Roland Sciences Po July 2011 Motivation After estimation, delivering information involves testing hypotheses Did this drug had any effect on the survival rate? Is this drug
More informationHierarchical expectation propagation for Bayesian aggregation of average data
Hierarchical expectation propagation for Bayesian aggregation of average data Andrew Gelman, Columbia University Sebastian Weber, Novartis also Bob Carpenter, Daniel Lee, Frédéric Bois, Aki Vehtari, and
More informationChapter Three. Hypothesis Testing
3.1 Introduction The final phase of analyzing data is to make a decision concerning a set of choices or options. Should I invest in stocks or bonds? Should a new product be marketed? Are my products being
More informationThe Design of Group Sequential Clinical Trials that Test Multiple Endpoints
The Design of Group Sequential Clinical Trials that Test Multiple Endpoints Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Bruce Turnbull
More informationPhase I design for locating schedule-specific maximum tolerated doses
Phase I design for locating schedule-specific maximum tolerated doses Nolan A. Wages, Ph.D. University of Virginia Division of Translational Research & Applied Statistics Department of Public Health Sciences
More informationTechnical Manual. 1 Introduction. 1.1 Version. 1.2 Developer
Technical Manual 1 Introduction 1 2 TraditionalSampleSize module: Analytical calculations in fixed-sample trials 3 3 TraditionalSimulations module: Simulation-based calculations in fixed-sample trials
More informationProbabilistic modeling. The slides are closely adapted from Subhransu Maji s slides
Probabilistic modeling The slides are closely adapted from Subhransu Maji s slides Overview So far the models and algorithms you have learned about are relatively disconnected Probabilistic modeling framework
More informationMixtures of multiple testing procedures for gatekeeping applications in clinical trials
Research Article Received 29 January 2010, Accepted 26 May 2010 Published online 18 April 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.4008 Mixtures of multiple testing procedures
More informationOptimal group sequential designs for simultaneous testing of superiority and non-inferiority
Optimal group sequential designs for simultaneous testing of superiority and non-inferiority Fredrik Öhrn AstraZeneca R & D Mölndal, SE-431 83 Mölndal, Sweden and Christopher Jennison Department of Mathematical
More informationMonitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs. Christopher Jennison
Monitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs Christopher Jennison Department of Mathematical Sciences, University of Bath http://people.bath.ac.uk/mascj
More informationUNIVERSITY OF TORONTO Faculty of Arts and Science
UNIVERSITY OF TORONTO Faculty of Arts and Science December 2013 Final Examination STA442H1F/2101HF Methods of Applied Statistics Jerry Brunner Duration - 3 hours Aids: Calculator Model(s): Any calculator
More informationRandomized dose-escalation design for drug combination cancer trials with immunotherapy
Randomized dose-escalation design for drug combination cancer trials with immunotherapy Pavel Mozgunov, Thomas Jaki, Xavier Paoletti Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics
More informationTests for the Odds Ratio of Two Proportions in a 2x2 Cross-Over Design
Chapter 170 Tests for the Odds Ratio of Two Proportions in a 2x2 Cross-Over Design Introduction Senn (2002) defines a cross-over design as one in which each subject receives all treatments and the objective
More informationAdaptive Treatment Selection with Survival Endpoints
Adaptive Treatment Selection with Survival Endpoints Gernot Wassmer Institut für Medizinische Statisti, Informati und Epidemiologie Universität zu Köln Joint wor with Marus Roters, Omnicare Clinical Research,
More informationMachine Learning Linear Classification. Prof. Matteo Matteucci
Machine Learning Linear Classification Prof. Matteo Matteucci Recall from the first lecture 2 X R p Regression Y R Continuous Output X R p Y {Ω 0, Ω 1,, Ω K } Classification Discrete Output X R p Y (X)
More informationclinical trials Abstract Multi-arm multi-stage (MAMS) trials can improve the efficiency of the drug
A multi-stage drop-the-losers design for multi-arm clinical trials James Wason 1, Nigel Stallard 2, Jack Bowden 1, and Christopher Jennison 3 1 MRC Biostatistics Unit, Cambridge 2 Warwick Medical School,
More informationIndividualized Treatment Effects with Censored Data via Nonparametric Accelerated Failure Time Models
Individualized Treatment Effects with Censored Data via Nonparametric Accelerated Failure Time Models Nicholas C. Henderson Thomas A. Louis Gary Rosner Ravi Varadhan Johns Hopkins University July 31, 2018
More informationBayesian Meta-analysis with Hierarchical Modeling Brian P. Hobbs 1
Bayesian Meta-analysis with Hierarchical Modeling Brian P. Hobbs 1 Division of Biostatistics, School of Public Health, University of Minnesota, Mayo Mail Code 303, Minneapolis, Minnesota 55455 0392, U.S.A.
More informationA Bayesian Stopping Rule for a Single Arm Study: with a Case Study of Stem Cell Transplantation
A Bayesian Stopping Rule for a Single Arm Study: with a Case Study of Stem Cell Transplantation Chao-Yin Chen Kathryn Chaloner University of Minnesota University of Iowa May-15-2002 1 A Case Study: MT9928
More informationCOMPOSITIONAL IDEAS IN THE BAYESIAN ANALYSIS OF CATEGORICAL DATA WITH APPLICATION TO DOSE FINDING CLINICAL TRIALS
COMPOSITIONAL IDEAS IN THE BAYESIAN ANALYSIS OF CATEGORICAL DATA WITH APPLICATION TO DOSE FINDING CLINICAL TRIALS M. Gasparini and J. Eisele 2 Politecnico di Torino, Torino, Italy; mauro.gasparini@polito.it
More informationThe SEQDESIGN Procedure
SAS/STAT 9.2 User s Guide, Second Edition The SEQDESIGN Procedure (Book Excerpt) This document is an individual chapter from the SAS/STAT 9.2 User s Guide, Second Edition. The correct bibliographic citation
More informationEstimation in Flexible Adaptive Designs
Estimation in Flexible Adaptive Designs Werner Brannath Section of Medical Statistics Core Unit for Medical Statistics and Informatics Medical University of Vienna BBS and EFSPI Scientific Seminar on Adaptive
More informationGroup Sequential Tests for Delayed Responses
Group Sequential Tests for Delayed Responses Lisa Hampson Department of Mathematics and Statistics, Lancaster University, UK Chris Jennison Department of Mathematical Sciences, University of Bath, UK Read
More informationPractical considerations for survival models
Including historical data in the analysis of clinical trials using the modified power prior Practical considerations for survival models David Dejardin 1 2, Joost van Rosmalen 3 and Emmanuel Lesaffre 1
More informationTESTS FOR EQUIVALENCE BASED ON ODDS RATIO FOR MATCHED-PAIR DESIGN
Journal of Biopharmaceutical Statistics, 15: 889 901, 2005 Copyright Taylor & Francis, Inc. ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400500265561 TESTS FOR EQUIVALENCE BASED ON ODDS RATIO
More informationNon-Inferiority Tests for the Ratio of Two Proportions in a Cluster- Randomized Design
Chapter 236 Non-Inferiority Tests for the Ratio of Two Proportions in a Cluster- Randomized Design Introduction This module provides power analysis and sample size calculation for non-inferiority tests
More informationIntroduction to Bayesian Statistics
Bayesian Parameter Estimation Introduction to Bayesian Statistics Harvey Thornburg Center for Computer Research in Music and Acoustics (CCRMA) Department of Music, Stanford University Stanford, California
More informationSequential Procedure for Testing Hypothesis about Mean of Latent Gaussian Process
Applied Mathematical Sciences, Vol. 4, 2010, no. 62, 3083-3093 Sequential Procedure for Testing Hypothesis about Mean of Latent Gaussian Process Julia Bondarenko Helmut-Schmidt University Hamburg University
More informationEvidence synthesis for a single randomized controlled trial and observational data in small populations
Evidence synthesis for a single randomized controlled trial and observational data in small populations Steffen Unkel, Christian Röver and Tim Friede Department of Medical Statistics University Medical
More informationTest Strategies for Experiments with a Binary Response and Single Stress Factor Best Practice
Test Strategies for Experiments with a Binary Response and Single Stress Factor Best Practice Authored by: Sarah Burke, PhD Lenny Truett, PhD 15 June 2017 The goal of the STAT COE is to assist in developing
More informationLing 289 Contingency Table Statistics
Ling 289 Contingency Table Statistics Roger Levy and Christopher Manning This is a summary of the material that we ve covered on contingency tables. Contingency tables: introduction Odds ratios Counting,
More informationSTAT Chapter 13: Categorical Data. Recall we have studied binomial data, in which each trial falls into one of 2 categories (success/failure).
STAT 515 -- Chapter 13: Categorical Data Recall we have studied binomial data, in which each trial falls into one of 2 categories (success/failure). Many studies allow for more than 2 categories. Example
More informationLecture 01: Introduction
Lecture 01: Introduction Dipankar Bandyopadhyay, Ph.D. BMTRY 711: Analysis of Categorical Data Spring 2011 Division of Biostatistics and Epidemiology Medical University of South Carolina Lecture 01: Introduction
More informationSAS/STAT 15.1 User s Guide The SEQDESIGN Procedure
SAS/STAT 15.1 User s Guide The SEQDESIGN Procedure This document is an individual chapter from SAS/STAT 15.1 User s Guide. The correct bibliographic citation for this manual is as follows: SAS Institute
More informationModel Averaging (Bayesian Learning)
Model Averaging (Bayesian Learning) We want to predict the output Y of a new case that has input X = x given the training examples e: p(y x e) = m M P(Y m x e) = m M P(Y m x e)p(m x e) = m M P(Y m x)p(m
More informationCOS513 LECTURE 8 STATISTICAL CONCEPTS
COS513 LECTURE 8 STATISTICAL CONCEPTS NIKOLAI SLAVOV AND ANKUR PARIKH 1. MAKING MEANINGFUL STATEMENTS FROM JOINT PROBABILITY DISTRIBUTIONS. A graphical model (GM) represents a family of probability distributions
More informationPMR Learning as Inference
Outline PMR Learning as Inference Probabilistic Modelling and Reasoning Amos Storkey Modelling 2 The Exponential Family 3 Bayesian Sets School of Informatics, University of Edinburgh Amos Storkey PMR Learning
More information27 : Distributed Monte Carlo Markov Chain. 1 Recap of MCMC and Naive Parallel Gibbs Sampling
10-708: Probabilistic Graphical Models 10-708, Spring 2014 27 : Distributed Monte Carlo Markov Chain Lecturer: Eric P. Xing Scribes: Pengtao Xie, Khoa Luu In this scribe, we are going to review the Parallel
More informationBayesian Updating: Discrete Priors: Spring
Bayesian Updating: Discrete Priors: 18.05 Spring 2017 http://xkcd.com/1236/ Learning from experience Which treatment would you choose? 1. Treatment 1: cured 100% of patients in a trial. 2. Treatment 2:
More information